|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Moreno V, Salazar R and Gruber SB: The
prognostic value of TILs in stage III colon cancer must consider
sidedness. Ann Oncol. 33:1094–1096. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Soeratram TTD, Beentjes I, Egthuijsen JMP,
Mookhoek A, Lange MM, Meershoek-Klein Kranenbarg E, Hartgrink HH,
van de Velde CJH, Ylstra B, van Laarhoven HWM and van Grieken NCT:
A biopsy-based immunoscore in patients with treatment-naive
resectable gastric cancer. Ther Adv Med Oncol.
16(17588359241287747)2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Doi S, Yasuda S, Miyashita M, Nagai M,
Nakamura K, Matsuo Y, Terai T, Kohara Y, Sakata T and Sho M:
Prognostic relevance of sarcopenia and tumor-infiltrating CD8(+) T
cells in patients with hepatocellular carcinoma. Ann Gastroenterol
Surg. 9:359–368. 2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kong D, Gao C, Yu Y, Yang L, Ma J, Tang S,
Mao Y, Li Y and Li N: The distribution characteristics of PD-1
pathway-related immune cells in esophageal cancer tissue and their
prognostic significance. PLoS One. 20(e0325349)2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang C, Chen F, Li J, He Y, Sun J, Zheng
Z, Liu G, Wang Y, Kang W and Ye X: Comprehensive analysis of
single-cell and bulk RNA sequencing data unveils antigen-presenting
and processing fibroblasts and establishes a predictive model in
gastric cancer. Cancer Cell Int. 25(225)2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pinkert J, Boehm HH, Trautwein M, Doecke
WD, Wessel F, Ge Y, Gutierrez EM, Carretero R, Freiberg C, Gritzan
U, et al: T cell-mediated elimination of cancer cells by blocking
CEACAM6-CEACAM1 interaction. Oncoimmunology.
11(2008110)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li Y, Polyak D, Lamsam L, Connolly ID,
Johnson E, Khoeur LK, Andersen S, Granucci M, Stanley G, Liu B, et
al: Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in
lung cancer leptomeningeal metastases. NPJ Precis Oncol.
5(90)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Huskey ALW, McNeely I and Merner ND:
CEACAM gene family mutations associated with inherited breast
cancer risk-A comparative oncology approach to discovery. Front
Genet. 12(702889)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ilantzis C, DeMarte L, Screaton RA and
Stanners CP: Deregulated expression of the human tumor marker CEA
and CEA family member CEACAM6 disrupts tissue architecture and
blocks colonocyte differentiation. Neoplasia. 4:151–163.
2002.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wu G, Wang D, Xiong F, Wang Q, Liu W, Chen
J and Chen Y: The emerging roles of CEACAM6 in human cancer
(Review). Int J Oncol. 64(27)2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang X, Yang C, Wang X and Duan P:
Pan-cancer analysis reveals a regulatory pattern of anoikis in
human cancers. Cell Mol Biol (Noisy-le-grand). 70:51–61.
2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zang M, Zhang B, Zhang Y, Li J, Su L, Zhu
Z, Gu Q, Liu B and Yan M: CEACAM6 promotes gastric cancer invasion
and metastasis by inducing epithelial-mesenchymal transition via
PI3K/AKT signaling pathway. PLoS One. 9(e112908)2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li Y, Zhu X, You J, Zhang B, Huang X and
Jin C: Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined
with anti-PD1 antibody in MC38 tumor model of mice. Heliyon.
8(e10775)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu Y, Xia T, Jin C, Gu D, Yu J, Shi W,
Zhang KE, Zhang L, Ye J and Li L: FOXP3 and CEACAM6 expression and
T cell infiltration in the occurrence and development of colon
cancer. Oncol Lett. 11:3693–3701. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Karamchandani DM, Gonzalez RS, Lee H,
Westerhoff M, Cox B and Pai RK: Interobserver agreement and
practice patterns for grading of colorectal carcinoma: World health
organization (WHO) classification of tumours 5th edition vs.
American joint committee on cancer (AJCC) 8th edition staging
manual. Histopathology. 86:1101–1111. 2025.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
The 2019 WHO classification of tumours of the digestive system.
Histopathology. 76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Condurache Hritcu OM, Ciobanu Apostol DG,
Toader SV, Solcan C, Brănișteanu DE, Toader MP and Costan VV:
Immunohistochemical assessment of maspin, β-catenin, and MMP-14 in
oral potentially malignant lesions and oral squamous cell
carcinoma: A retrospective observational study. Medicina (Kaunas).
61(1037)2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Menard LC, Fischer P, Kakrecha B, Linsley
PS, Wambre E, Liu MC, Rust BJ, Lee D, Penhallow B, Manjarrez Orduno
N and Nadler SG: Renal cell carcinoma (RCC) tumors display large
expansion of double positive (DP) CD4+CD8+ T cells with expression
of exhaustion markers. Front Immunol. 9(2728)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huang CY, Chiang SF, Ke TW, Chen TW, You
YS, Chen WT and Chao KSC: Clinical significance of programmed death
1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration
in stage II-III colorectal cancer. Sci Rep. 8(15658)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Thomas CE, Takashima Y, Buchanan DD,
Wesselink E, Qu C, Hsu L, Dias Costa A, Gallinger S, Grant RC,
Huyghe JR, et al: Density of T-cell subsets in colorectal cancer in
relation to disease-specific survival. Cancer Epidemiol Biomarkers
Prev. 34:1122–1133. 2025.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Küçükköse E, Baars MJD, Amini M, Schraa
SJ, Floor E, Bol GM, Borel Rinkes IHM, Roodhart JML, Koopman M,
Laoukili J, et al: Stromal localization of inactive CD8(+) T cells
in metastatic mismatch repair deficient colorectal cancer. Br J
Cancer. 130:213–223. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Prasongtanakij S, Soontrapa K and Thumkeo
D: The role of prostanoids in regulatory T cells and their
implications in inflammatory diseases and cancers. Eur J Cell Biol.
104(151482)2025.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Martinez-Rios J, Lopez-Pacheco CP,
Garcia-Zepeda EA and Soldevila G: CCR9 shapes the immune
microenvironment of colorectal cancer modulating the balance
between intratumoral CD8+ T cell and FoxP3+ Helios+ Treg
subpopulations. PLoS One. 20(e0321930)2025.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tanaka A and Sakaguchi S: Targeting treg
cells in cancer immunotherapy. Eur J Immunol. 49:1140–1146.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tanaka A and Sakaguchi S: Regulatory T
cells in cancer immunotherapy. Cell Res. 27:109–118.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shah F, Giri PS, Bharti AH and Dwivedi M:
Compromised melanocyte survival due to decreased suppression of
CD4(+) & CD8(+) resident memory T cells by impaired
TRM-regulatory T cells in generalized vitiligo patients. Exp
Dermatol. 33(e14982)2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Panek WK, Toedebusch RG, McLaughlin BE,
Dickinson PJ, Van Dyke JE, Woolard KD, Berens ME, Lesniak MS,
Sturges BK, Vernau KM, et al: The CCL2-CCR4 axis promotes
regulatory T cell trafficking to canine glioma tissues. J
Neurooncol. 169:647–658. 2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Redin E, Garmendia I, Lozano T, Serrano D,
Senent Y, Redrado M, Villalba M, De Andrea CE, Exposito F, Ajona D,
et al: SRC family kinase (SFK) inhibitor dasatinib improves the
antitumor activity of anti-PD-1 in NSCLC models by inhibiting treg
cell conversion and proliferation. J Immunother Cancer.
9(e001496)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nakazawa Y, Miyano M, Tsukamoto S, Kogai
H, Yamamoto A, Iso K, Inoue S, Yamane Y, Yabe Y, Umihara H, et al:
Delivery of a BET protein degrader via a CEACAM6-targeted
antibody-drug conjugate inhibits tumour growth in pancreatic cancer
models. Nat Commun. 15(2192)2024.PubMed/NCBI View Article : Google Scholar
|
